Gyre Therapeutics Inc. (GYRE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.55 (+5.15%), Market cap $0.68B, 52-week low–high $6.55 ~ $11.40.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In
Financial statements, price targets, institutional (13F) holdings and related news for Gyre Therapeutics Inc. are updated in real time on BlackAll Trade.
Gyre Therapeutics Inc. trades at $7.55 (+5.15%). Real-time quotes and charts are available on BlackAll Trade.
Gyre Therapeutics Inc. has a market cap of about $0.68B.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company